FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2024-02-26
0
0
0
-
2023-11-07
0
0
0
-
2023-08-18
0
0
0
-
2023-06-23
0
0
-0.34
-
2023-02-24
0
-0.61
0
-
2022-11-09
0
-0.37
-0.42
-11.90%
2022-08-09
0
-0.49
-0.52
-5.77%
2022-05-10
0
-0.58
-0.57
1.75%
2022-02-25
0
-0.61
-0.58
5.17%
2021-11-08
0
-0.55
-0.56
-1.79%
2021-08-09
0
-0.56
-0.48
16.67%
2021-05-10
0
-0.51
-0.54
-5.56%
2021-02-23
0
-0.5
-0.53
-5.66%
2020-11-09
0
-0.51
-0.5
2.00%
2020-08-10
0
-0.47
-0.54
-12.96%
2020-05-11
0
-0.6
-0.57
5.26%
2020-03-12
0
-0.56
-0.6
-6.67%
2019-11-14
0
-0.59
-0.53
11.32%
2019-08-13
0
-0.5
-0.46
8.70%
2019-05-15
0
-0.42
-0.38
10.53%
2019-03-28
0
-0.35
-0.42
-16.67%
2018-11-13
0
-0.42
-0.36
16.67%
2018-07-18
0
-0.38
-0.3
26.99%
2018-03-31
0
-1.83
0
-
2017-12-31
0
-2.01
0
-
2017-09-30
0
-1.37
0
-
2017-06-30
0
-1.09
0
-
2017-03-31
0
-0.56
0
-
